Drug Trial Radar · NCT07266805
Study of Oral Deucrictibant XR Tablet for Prophylaxis and Deucrictibant Soft Capsule for On-Demand Treatment of Angioedema Attacks in Adults With Acquired Angioedema Due to C1 Inhibitor Deficiency
Last checked: Nov 19, 2026Latest source record: Sep 21, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
48
Planned (sponsor's estimate)
Start
Oct 16, 2025
Primary completion
Jun 2027
Study completion Jun 2027
Sponsor
- Lead sponsor
- Pharvaris Netherlands B.V.Industry
- Sponsor type
- Industry
- First posted
- Dec 5, 2025
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a Phase 3, multicenter, 3-part study, with 2 randomized, double-blind, placebo-controlled parts and an open-label extension part, to evaluate the efficacy and safety of orally administered deucrictibant XR tablet for prophylaxis, and deucrictibant soft capsule for on-demand treatment of angioedema attacks in adult participants aged ≥ 18 years with AAE-C1INH.
Conditions
- Acquired Angioedema Due to C1-Inhibitor Deficiency (AAE-C1-INH)
Interventions
DeucrictibantDrug
Part 1: Deucrictibant 40 mg extended-release tablet for once daily oral use
PlaceboDrug
Part 1: Placebo Comparator tablet for once daily oral use
DeucrictibantDrug
Part 2: Deucrictibant 20 mg soft capsule oral use
PlaceboDrug
Part 2: Placebo Comparator soft capsule oral use
DeucrictibantDrug
Part 3: Deucrictibant 20 mg soft capsule oral use
Primary outcomes
What the sponsor says the trial is designed to measure.
- Part 1: Time-normalized number of Investigator-confirmed AAE-C1INH attacks during Treatment PhaseTime frame: 12 weeks
- Part 2: Time to symptom relief, Patient Global Impression of Change (PGI-C) rating of at least "better"Time frame: 12 hours post-treatment
- Part 3: Incidence of treatment-emergent adverse events (TEAEs), treatment-emergent adverse events of special interest (AESIs), and serious adverse events (SAEs)Time frame: Through study termination, an average of 36 weeks
- Part 3: Number of participants with clinically significant changes from baseline in Hematology parametersTime frame: Through study termination, an average of 36 weeks
- Part 3: Number of participants with clinically significant changes from baseline in Urinalysis parametersTime frame: Through study termination, an average of 36 weeks
- Part 3: Number of participants with clinically significant changes from baseline in Biochemistry parametersTime frame: Through study termination, an average of 36 weeks
- Part 3: Number of participants with clinically significant changes from baseline in vital signsTime frame: Through study termination, an average of 36 weeks
- Part 3: Number of participants with clinically significant changes from baseline in physical examinationsTime frame: Through study termination, an average of 36 weeks
- Part 3: Number of participants with clinically significant changes in electrocardiogram (ECG)Time frame: Through study termination, an average of 36 weeks
Locations
32 sites in 16 countries. Site status is shown where the registry gives one.
Study Site
San Diego, California · Recruiting
Study Site
Walnut Creek, California · Recruiting
Study Site
St Louis, Missouri · Recruiting
Study Site
Hershey, Pennsylvania · Recruiting
Study Site
Clayton, Australia · Recruiting
Study Site
Vienna, Austria · Recruiting
Study Site
Sofia, Bulgaria · Recruiting
Study Site
Edmonton, Canada · Recruiting
Study Site
Grenoble, France · Recruiting
Study Site
Lille, France · Recruiting
Study Site
Paris, France · Recruiting
Study Site
Berlin, Germany · Recruiting
Study Site
Frankfurt am Main, Germany · Recruiting
Study Site
Munich, Germany · Recruiting
Study Site
Budapest, Hungary · Recruiting
Study Site 1
Milan, Italy · Recruiting
Study Site 2
Milan, Italy · Recruiting
Study Site 3
Milan, Italy · Recruiting
Study Site
Padova, Italy · Recruiting
Study Site
Roma, Italy · Recruiting
Study Site
Amsterdam, Netherlands · Recruiting
Study Site
Auckland, New Zealand · Recruiting
Study Site
Krakow, Poland · Recruiting
Study Site
Madrid, Spain · Recruiting
Study Site
Basel, Switzerland · Recruiting
Study Site
Ankara, Turkey (Türkiye) · Recruiting
Study Site
Bristol, United Kingdom · Recruiting
Study Site
Cambridge, United Kingdom · Recruiting
Study Site
Leicester, United Kingdom · Recruiting
Study Site
London, United Kingdom · Recruiting
Study Site
Newcastle upon Tyne, United Kingdom · Recruiting
Study Site
Plymouth, United Kingdom · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.